Journal of Hepatology (J HEPATOL)

Publications in this journal

• Article: Global burden of alcoholic liver diseases

  Rehm J, Samokhvalov AV, Shield KD
  Journal of Hepatology 03/2013;
• Article: Reply to "Association between IL28B polymorphism and treatment response in patients with genotype 4 chronic hepatitis C": HCV genotype 4 infection: A major medical need.

  Emilie Estrabaud, Olivier Lada, Tarik Asselah
  Journal of Hepatology 06/2012;
• Article: Reply to "Liver in mythology: A different version of Tityos' myth": Liver, snakes and myths.

  Michele A Riva
  Journal of Hepatology 05/2012;
• Article: Reply to "IBD is associated with an increase in carcinoma in PSC irrespective of the presence of dominant bile duct stenosis".

  Daniel N Gotthardt, Adolf Stiehl
  Journal of Hepatology 04/2012; 57(2):475.
• Article: Reply to "Biliary atresia: Does ethnicity matter?"

  Cyriel Y Ponsioen, Kirsten Boonstra
  Journal of Hepatology 04/2012;
• Article: Reply to: "Statin hepatotoxicity and the dilemma of causality in rare hepatic adverse drug reactions"

  Ted Bader
  Journal of Hepatology 04/2012;
• Article: Reply to: Platelet function in patients with cirrhosis.

  Francesco Violi, Stefania Basili, Valeria Raparelli, Pratima Chowdary, Alexander Gatt, Andrew K Burroughs
  Journal of Hepatology 04/2012; 56(4):994-5.
• Article: LONG-TERM (LT) THERAPY OF A FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) MAINTAINS BIOCHEMICAL RESPONSE IN PRIMARY BILIARY CIRRHOSIS (PBC)

  G Hirschfield, K Kowdley, A Mason, V Luketic, S Gordon, C Vincent, M Mayo, A Pares, R Chapman, K Lindor, M Esguerra, L Eliot, D Shapiro
  Journal of Hepatology 04/2012; 56(2}, Meeting Abstract = {952):S372.
• Article: EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma.

  European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer
  Journal of Hepatology 04/2012; 56(4):908-43.
• Article: THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) INCREASES PLASMA FGF-19 CONCENTRATIONS AND DECREASES BILE ACID SYNTHESIS IN PRIMARY BILIARY CIRRHOSIS (PBC)

  H -U Marschall, V Luketic, A Lovgren-Sandblom, L Benthin, K Kowdley, G Hirschfield, A Mason, K Lindor, S Gordon, C Vincent, R Chapman, M Mayo, A Burroughs, A Pares, D Jones, C Schramm, L Eliot, A F Hofmann, D Shapiro
  Journal of Hepatology 04/2012; 56(2}, Meeting Abstract = {964):S377.
• Article: SERUM AUTOTAXIN ACTIVITY IS ASSOCIATED WITH PRURITUS AND DISEASE DURATION AND SEVERITY IN PRIMARY BILIARY CIRRHOSIS

  A Pares, A E Kremer, L Caballeria, Oude R P Elferink, A Mas, U Beuers
  Journal of Hepatology 04/2012; 56(2}, Meeting Abstract = {970):S379-S380.
• Article: SERUM METABOLOMIC PROFILING IN PATIENTS WITH CHOLESTATIC PRURITUS

  A Pares, M Perez-Cormenzana, R Mayo, A Bennasar, A Mas, A Castro
  Journal of Hepatology 04/2012; 56(2}, Meeting Abstract = {38):S17.
• Article: EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection.

  European Association For The Study Of The Liver
  Journal of Hepatology 03/2012; 57(1):167-85.
• Article: Reply to: "The "pegylated" story continues - Perhaps because both ends (α2a and α2b) are true?".

  Alessio Aghemo, Gian Maria Prati, Massimo Colombo
  Journal of Hepatology 03/2012; 57(1):229.
• Article: Reply to: "Patients with cirrhosis admitted to an Intensive Care Unit".

  Eric Levesque, Faouzi Saliba, Didier Samuel
  Journal of Hepatology 03/2012; 57(1):231-2.
• Article: Reply to: "Favorable association between genetic polymorphisms near the IL28B gene and hepatic steatosis: Direct or indirect?".

  Hans Ludger Tillmann, Jeanette J McCarthy
  Journal of Hepatology 03/2012; 56(3):739.
• Article: EASL Clinical Practice Guidelines: Wilson's disease.

  European Association For The Study Of The Liver
  [show abstract] [hide abstract]
  ABSTRACT: This Clinical Practice Guideline (CPG) has been developed to assist physicians and other healthcare providers in the diagnosis and management of patients with Wilson's disease. The goal is to describe a number of generally accepted approaches for diagnosis, prevention, and treatment of Wilson's disease. Recommendations are based on a systematic literature review in the Medline (PubMed version), Embase (Dialog version), and the Cochrane Library databases using entries from 1966 to 2011. The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system used in other EASL CPGs was used and set against the somewhat different grading system used in the AASLD guidelines (Table 1A and B). Unfortunately, there is not a single randomized controlled trial conducted in Wilson's disease which has an optimal design. Thus, it is impossible to assign a high or even a moderate quality of evidence to any of the questions dealt with in these guidelines. The evaluation is mostly based on large case series which have been reported within the last decades.
  Journal of Hepatology 03/2012; 56(3):671-85.
• Article: Reply to "IL28B polymorphism and hepatitis C: A genetic marker of peginterferon-α sensitivity devoid from classical interferon-α side effects?".

  A J Thompson, P J Clark, A J Muir, M S Sulkowski
  Journal of Hepatology 03/2012; 56(3):742-3.